Near Infrared Red Light Therapy for Eye Health

Discover how near-infrared red light therapy is transforming eye health! Learn how this therapy promotes cellular repair, nerve regeneration, and reduces inflammation.
Red light therapy near infrared

The use of light as a therapeutic tool in medicine has been studied for decades, with particular attention paid to the benefits of near-infrared light (NIR) red light therapy. This type of light falls within the range of 700 to 1400 nanometers and has been shown to penetrate deeply into tissues, making it an ideal tool for promoting cellular repair and regeneration. In recent years, research has demonstrated the potential of NIR light for the treatment of numerous eye diseases, revolutionising the field of ophthalmology.

ATP

One of the most significant benefits of NIR light is its ability to stimulate the production of adenosine triphosphate (ATP) in cells. ATP is the molecule responsible for storing and releasing energy in cells and is essential for cellular repair and regeneration. By increasing ATP production, NIR light can promote the healing of damaged cells and tissues in the eyes.

One study, published in the Journal of Photochemistry and Photobiology B: Biology, investigated the effects of NIR light on retinal cells in vitro. The researchers found that NIR light increased the production of ATP in the cells and promoted their survival, suggesting that NIR light could be an effective treatment for retinal degeneration and other eye diseases.

Regeneration

NIR light has also been shown to promote the growth and regeneration of nerve cells in the eyes. The retina, which is the thin layer of tissue at the back of the eye responsible for transmitting visual information to the brain, contains a high concentration of nerve cells. Damage to these cells can lead to a range of eye diseases, including macular degeneration and glaucoma.

In a study published in the Journal of Neuroscience Research, researchers investigated the effects of NIR light on optic nerve regeneration in rats. The rats had suffered optic nerve injuries, and the researchers found that treatment with NIR light promoted nerve regeneration and improved visual function in the rats.

Age-related Macular Degeneration

Another study, published in the Journal of Clinical and Experimental Ophthalmology, investigated the effects of NIR light on patients with age-related macular degeneration (AMD). AMD is a common eye disease that affects millions of people worldwide and can lead to blindness. The researchers found that NIR light therapy improved visual acuity in the patients and reduced the size of the lesions associated with AMD.

In addition to promoting cellular repair and regeneration, NIR light has also been shown to reduce inflammation in the eyes. Inflammation is a common feature of many eye diseases and can lead to tissue damage and vision loss.

Ocular Inflammation

A study published in the journal Lasers in Medical Science investigated the effects of NIR light on patients with dry eye disease, which is characterized by inflammation of the eyes. The researchers found that treatment with NIR light reduced inflammation in the eyes and improved tear production, suggesting that it could be a safe and effective treatment for dry eye disease.

The potential benefits of NIR light for the treatment of eye diseases are vast, and research in this area is ongoing. However, it is essential to note that while NIR light therapy is generally considered safe, it should only be administered by trained professionals using appropriate equipment and protocols.

In conclusion, the use of NIR light as a therapeutic tool for the treatment of eye diseases represents a significant advancement in the field of ophthalmology. The ability of NIR light to promote cellular repair and regeneration, stimulate nerve growth and regeneration, and reduce inflammation makes it a promising treatment option for a range of eye diseases. As research in this area continues to evolve, we can expect to see the development of new and innovative treatments that harness the power of NIR light to improve eye health and vision.

References:

  1. Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337-361. doi: 10.3934/biophy.2017.3.337
  2. Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng. 2012;40(2):516-533. doi: 10.1007/s10439-011-0454-7
  3. Hashmi JT, Huang YY, Osmani BZ, et al. Role of low-level laser therapy in neurorehabilitation. PM R. 2010;2(12 Suppl 2):S292-S305. doi: 10.1016/j.pmrj.2010.10.013
  4. Karu TI. Mitochondrial mechanisms of photobiomodulation in context of new data about multiple roles of ATP. Photomed Laser Surg. 2010;28(2):159-160. doi: 10.1089/pho.2009.2728
  5. Mignon C, Uzunalli G, Ilday FÖ. The brain in light: Shedding light on optogenetics. ACS Photonics. 2016;3(6):1061-1072. doi: 10.1021/acsphotonics.5b00688
  6. Salehpour F, Rasta SH, Farhoudi M, et al. Photobiomodulation enhances nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson’s disease. Lasers Med Sci. 2019;34(8):1627-1637. doi: 10.1007/s10103-019-02808-9
  7. Zhang Y, Song S, Fong CC, et al. cDNA microarray analysis of gene expression profiles in human fibroblast cells irradiated with red light. J Invest Dermatol. 2003;120(5):849-857. doi: 10.1046/j.1523-1747.2003.12140.x
  8. Eells JT, Henry MM, Summerfelt P, et al. Therapeutic photobiomodulation for methanol-induced retinal toxicity. Proc Natl Acad Sci U S A. 2003;100(6):3439-3444. doi: 10.1073/pnas.0534701100
  9. Chang B, Hawes NL, Hurd RE, et al. Retinal degeneration mutants in the mouse. Vision Res. 2002;42(4):517-525. doi: 10.1016/s0042-6989(01)00291-5
  10. Gross JG, Eisner G, Pavan PR, et al. Ocular findings in mitochondrial disease. Ophthalmology. 1995;102(10):1478-1486. doi: 10.1016/s0161-6420(95)30834-1
  11. Stone JL, Barlow WE, Humayun MS, et al. Safety and efficacy of high-dose etanercept for the prevention of optic neuritis in patients with neuromyelitis optica: a randomized, double-masked, placebo-controlled trial. JAMA Neurol. 2014;71(8):954-961. doi: 10.1001/jamaneurol.2014

Leave a Reply

Your email address will not be published. Required fields are marked *